Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002772 · ClinicalTrials.gov registry record · Phase 3

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

A Phase 3 study, sponsored by SWOG Cancer Research Network.

Terminated
Registry status
Phase 3
Development phase
602
Enrollment target

NCT00002772: Clinical Trial Phase 3 study, sponsored by SWOG Cancer Research Network.

NCT00002772 is a Phase 3 study that was terminated before completion, run by SWOG Cancer Research Network. The registered enrollment target is 602 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002772, a Phase 3 study, was terminated before completion, sponsored by SWOG Cancer Research Network.

TERMINATED
Registry status
Phase 3
Development phase
602 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which regimen of chemotherapy followed by peripheral stem cell transplantation is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating women who have undergone surgery for breast cancer.

Interventions

  • DRUG cisplatin
  • DRUG carboplatin
  • DRUG cyclophosphamide
  • DRUG carmustine
  • BIOLOGICAL filgrastim

Trial Details

FieldValue
Enrollment Target 602 participants
Start Date 1996-07
Est. Completion 2004-02
Phase Phase 3
SWOG Cancer Research Network

270 total trials

Why NCT00002772 stopped before completion

NCT00002772 is an interventional study that assigns participants to a tested intervention. The registered 602 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).

The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.

NCT00002772 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002772 about?

NCT00002772 is a clinical study titled "S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which regimen of chemotherapy fo...

What is the current status of trial NCT00002772?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 1996-07. Estimated completion is 2004-02.

What interventions are being tested in trial NCT00002772?

The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), cyclophosphamide (DRUG), carmustine (DRUG), filgrastim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002772?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00002772's enrollment target sits among peer trials

602 607th of 2000 higher than 1,393 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03849443 · 604 participants · Early Phase 1

    Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

  • NCT05238922 · 604 participants · Phase 1

    Study of INCB123667 in Subjects With Advanced Solid Tumors

  • NCT06040541 · 604 participants · Phase 1

    Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002772, the US trial registry maintained by the National Library of Medicine. NCT00002772 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.